Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 11 de 11 
Presentar resultados
Seleccionar todas
1. Cita con resumen
van Eijk AM, Zulaika G, Lenchner M, Mason L, Sivakami M, Nyothach E, Unger H, Laserson KFPhillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. The Lancet Public Health 2019;4:1. [Ref.ID 103161]
2.Enlace a cita original Cita con resumen
Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, Jackson L, Keogh M, Lawrence T, Montgomery AA, Roberts TE, Sprange K, Tan W, Thandi S, Wilson J, Duley L, on behalf of the G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet 2019:2 de mayo. [Ref.ID 103140]
3.Enlace a cita original Cita con resumen
Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]
4.Enlace a cita original Cita con resumen
Taylor SN, Marrazzo J, Batteiger BE, Hook III EW, Seña AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, Mueller J. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med 2018;379:8 de noviembre. [Ref.ID 102865]
5. Cita con resumen
Anónimo. FDA warns SGLT2 inhibitors can cause flesh-eating genitali infection. DIA Daily 2018:1. [Ref.ID 102830]
6.Tiene citas relacionadas
Weinstein RA, Boyer KM. Antibiotic prophylaxis for cesarean delivery - When broader is better. N Engl J Med 2016;375:1284-6. [Ref.ID 100771]
7.Tiene citas relacionadas Cita con resumen
Tita ATN, Szychowski JM, Boggess K, Saade G, Longo S, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W, for the C/SOAP Trial Consortium. Adjunctive azithromycin prophylaxis for cesarean delivery. N Engl J Med 2016;375:1231-41. [Ref.ID 100770]
8. Cita con resumen
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34. [Ref.ID 100645]
9. Cita con resumen
Schachter J. Azithromycin versus doxycycline for Chlamydia. N Engl J Med 2016;374:1786-7. [Ref.ID 100225]
10. Cita con resumen
Geisler WM, Uniyal A, Lee JY, Lensing SY, Johnson S, Perry RCW, Kadrnka CM, Kerndt PR. Azithromycin versus doxycycline for urogenital Chlamydia trachomatis infection. N Engl J Med 2015;373:2512-21. [Ref.ID 99766]
11. Cita con resumen
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. [Ref.ID 99479]
Seleccionar todas
 
 1 a 11 de 11